|
|
|
| Clinical study of Bevacizumab combined with Paclitaxel Liposome and Tegafur Gimeracil and Oteracil Potassium in the treatment of medium and advanced gastric cancer |
| XU Zhen ZUO Yun LU Weidong |
| Oncology Department, Zhangjiagang First People′s Hospital, Jiangsu Province, Zhangjiagang 215600, China |
|
|
|
Abstract Objective To study the clinical effect of Bevacizumab combined with Paclitaxel Liposome and Tegafur Gimeracil and Oteracil Potassium in the treatment of medium and advanced gastric cancer. Methods Ninety patients with medium and advanced gastric cancer who were treated in the Oncology Department of Zhangjiagang First People′s Hospital from April 2012 to December 2017 were selected and divided into study group and control group according to different treatment methods, with 45 cases in each group. The control group was treated with Paclitaxel Liposome combined with Tegafur Gimeracil and Oteracil Potassium, while the study group was treated with Bevacizumab on the basis of the control group. The clinical efficacy, serum carbohydrate antigen 724 (CA724), carbohydrate antigen 199 (CA199) levels, adverse reactions, quality of life and immune function were compared between the two groups. Results The total effective rate of the study group (88.89%) was higher than that of the control group (68.89%), and the difference was statistically significant (P ＜ 0.05). The levels of CA724 and CA199 in the two groups after treatment were significantly lower than before treatment, and the differences were all highly statistically significant (all P ＜ 0.01). The levels of serum CA724 and CA199 in the study group were all significantly lower than those in the control group, and the differences were all highly statistically significant (all P ＜ 0.01). There were no significant differences in the incidence of leukopenia, nausea and vomiting, abnormal renal and liver function and alopecia between the two groups (all P ＞ 0.05). The Karnofsky performance score of the study group was significantly higher than that of the control group after treatment, and the difference was highly statistically significant (P ＜ 0.01). The levels of CD4+ and CD4+/CD8+ in the study group were significantly higher than those in the control group, and the differences were statistically significant (P ＜ 0.05 or P ＜ 0.01). Conclusion Bevacizumab combined with Paclitaxel Liposome and Tegafur Gimeracil and Oteracil Potassium is effective in the treatment of medium and advanced gastric cancer. It is worth popularizing and applying.
|
|
|
|
|
|
[1] 朱雪玲，沈国平，巩海凤，等.EZR、NF2基因在胃癌细胞中的表达[J].中国高原医学与生物学杂志，2017，38（4）：256-261.
[2] 何耀明，马娟.胃癌患者术后应用贝伐珠单抗联合化疗的不良反应防治[J].中国综合临床，2016，32（5）：400-403.
[3] 王德华.贝伐珠单抗联合化学药物治疗晚期胃癌的疗效观察[J].中国生化药物杂志，2017，37（10）：237-238.
[4] 张国政，张金花，候慧科，等.贝伐珠单抗注射液联合5-氟尿嘧啶、顺铂腹腔灌注热化疗治疗中晚期胃癌的疗效及对血清肿瘤标志物水平的影响[J].肿瘤基础与临床，2018，31（1）：81-83.
[5] 季加孚.胃癌NCCN临床实践指南2009版解读[J].中华胃肠外科杂志，2009，12（2）：107-109.
[6] 李敬国，张明军，李娜，等.两种生活质量评分对甲磺酸伊马替尼治疗胃肠间质瘤患者生活质量评价的可行性[J].山东医药，2011，51（13）：33-34.
[7] 张贺龙.实体瘤疗效评价标准及演变[J].现代肿瘤医学，2010，18（5）：839-841.
[8] 贺华，周美红，张勇.贝伐单抗与卡培他滨联合奥沙利铂方案对老年晚期胃癌术后血清肿瘤标志物及生活质量的影响[J].中国药业，2017，26（5）：69-72.
[9] 彭为，王龙，王亚运，等.紫杉醇脂质体联合改良FOLFOX方案对胃癌术后复发的疗效观察[J].兰州大学学报：医学版，2017，43（3）：43-47.
[10] 蔡娟，左学良，赵文英，等.紫杉醇脂质体与紫杉醇联合替吉奥一线治疗晚期胃癌的疗效观察[J].皖南医学院学报，2018，37（3）：247-250.
[11] 郜娜娜，马馨，贺新爱.塞来昔布联合化疗治疗晚期胃癌的疗效分析[J].中国癌症防治杂志，2017，9（6）：478-481.
[12] 闫晓红，赵亚宁，汪华，等.阿帕替尼联合奥沙利铂+替吉奥治疗晚期胃癌效果观察[J].肿瘤研究与临床，2017，29（11）：761-764.
[13] 张瑾，刘艳屏.贝伐珠单抗联合紫杉醇脂质体对老年晚期胃癌患者血清CEA、CA199、MMP-2及MMP-9水平的影响[J].中国老年学杂志，2018，38（5）：1108-1110.
[14] 葛琳.紫杉醇脂质体联合贝伐珠单抗治疗中晚期胃癌的疗效及其对免疫功能的影响[J].中国基层医药，2018， 25（11）：1387-1390.
[15] 宁琳洪，谢霞，廖忠莉，等.贝伐珠单抗联合紫杉醇脂质体方案对晚期胃癌患者血清基质金属蛋白酶2和9及预后的影响[J].医学综述，2016，22（23）：4698-4700.
[16] 毕明宏.贝伐珠单抗治疗非小细胞肺癌进展[J].临床肺科杂志，2018，23（10）：1909-1914.
[17] 郭光爱，张玉红.加减补中益气汤联合奥沙利铂、替吉奥方案治疗晚期胃癌临床效果对比分析[J].中医临床研究，2018，10（19）：96-98.
[18] 李岚.贝伐珠单抗联合化疗治疗晚期胃癌的临床效果[J].国际医药卫生导报，2014，20（24）：3772-3773. |
|
|
|
